Since January 2018, the CardioVascular Center has published numerous reports in peer-reviewed journals. These are the highlighted high-impact manuscripts from this quarter.
Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, Kociol RD, Lewis EF, Mehra MR, Pagani FD, Raval AN, Ward C; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2018 May 15;137(20):e578-e622.
Published in Circulation (Impact Factor: 19). This consensus statement from the American Heart Association led by Drs. Konstam and Kiernan provides penetrating insight into the problem of right heart failure, which is a major cause of global morbidity and mortality for millions of individuals worldwide.
Morine KJ, Qiao X, York S, Natov PS, Paruchuri V, Zhang Y, Aronovitz MJ, Karas RH, Kapur NK. Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure. Circulation. 2018 Feb 27. pii:CIRCULATIONAHA.117.031635.
Published in Circulation (Impact Factor: 19). This original research report from led by Dr. Morine, an interventional cardiology fellow at Tufts Medical Center, introduces a new protein that regulates heart failure and may be a novel target of therapy for drug development. This work represents the culmination of Dr. Morine's research as a recipient of an award from the National Institutes of Health T-32 Post-doctoral Fellowship Program in Dr. Kapur’s Lab. The report was also highlighted in Nature Cardiovascular Medicine as pioneering work.
Wells S, Rowin EJ, Bhatt V, Maron MS, Maron BJ. Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy. Circulation. 2018 May 1;137(18):1973-1975.
Published in Circulation (Impact Factor: 19). This original research report identified that African American patients with HCM may be under-recognized and under-referred for effective therapies such as surgical myectomy or implantable cardioverter defibrillators because of potential racial disparities in access to specialty HCM care.